CBAY — CymaBay Therapeutics Share Price
0.000.00%
Last trade - 00:00- $3.73bn
- $3.44bn
- $31.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 12.76 | ||
| Price to Tang. Book | 12.76 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 119.98 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.56% | ||
| Return on Equity | -64.17% | ||
| Operating Margin | -327.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 31.07 | 2.45 | 83.75 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.
Directors
- Robert Wills NEC (67)
- Sujal Shah PRE (47)
- Charles McWherter SVP (66)
- Paul Quinlan CCO (58)
- Daniel Menold VFN (51)
- Klara Dickinson OTH (54)
- Dennis Kim OTH (50)
- Lewis Stuart OTH
- Janet Dorling DRC (47)
- Caroline Loewy IND (55)
- Kurt Von Emster IND (53)
- Thomas Wiggans IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 5th, 1988
- Public Since
- January 16th, 2014
- No. of Shareholders
- 172
- No. of Employees
- 108
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 114,785,001
- Address
- SUITE 130, 7999 GATEWAY BLVD, NEWARK, 94560
- Web
- https://www.cymabay.com/
- Phone
- +1 5102938800
- Contact
- Hans Vitzthum
- Auditors
- Ernst & Young LLP
Upcoming Events for CBAY
CymaBay Therapeutics Inc Annual Shareholders Meeting
Q2 2024 CymaBay Therapeutics Inc Earnings Release
Similar to CBAY
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the CymaBay Therapeutics share price?
As of Today at 18:06 UTC, shares in CymaBay Therapeutics are trading at $32.48. This share price information is delayed by 15 minutes.
How has the CymaBay Therapeutics share price performed this year?
Shares in CymaBay Therapeutics last closed at $32.48 and the price had moved by +269.51% over the past 365 days. In terms of relative price strength the CymaBay Therapeutics share price has outperformed the S&P500 Index by +180.33% over the past year.
What are the analyst and broker recommendations for CymaBay Therapeutics?
The overall consensus recommendation for CymaBay Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CymaBay Therapeutics dividend yield?
CymaBay Therapeutics does not currently pay a dividend.
Does CymaBay Therapeutics pay a dividend?
CymaBay Therapeutics does not currently pay a dividend.
When does CymaBay Therapeutics next pay dividends?
CymaBay Therapeutics does not currently pay a dividend.
How do I buy CymaBay Therapeutics shares?
To buy shares in CymaBay Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CymaBay Therapeutics?
As of the previous close price of $32.48, shares in CymaBay Therapeutics had a market capitalisation of $3.73bn.
Where are CymaBay Therapeutics shares listed?
Here are the trading details for CymaBay Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CBAY
What kind of share is CymaBay Therapeutics?
Based on an overall assessment of its quality, value and momentum CymaBay Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CymaBay Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in CymaBay Therapeutics is $32.50. That is 0.06% above the last closing price of $32.48.
Analysts covering CymaBay Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.52 for the next financial year.
Find out moreWhat is the trend in the CymaBay Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CymaBay Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +82.97%.
As of the last closing price of $32.48, shares in CymaBay Therapeutics were trading +76.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CymaBay Therapeutics PE Ratio?
The CymaBay Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $32.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CymaBay Therapeutics?
CymaBay Therapeutics' management team is headed by:
- Robert Wills - NEC
- Sujal Shah - PRE
- Charles McWherter - SVP
- Paul Quinlan - CCO
- Daniel Menold - VFN
- Klara Dickinson - OTH
- Dennis Kim - OTH
- Lewis Stuart - OTH
- Janet Dorling - DRC
- Caroline Loewy - IND
- Kurt Von Emster - IND
- Thomas Wiggans - IND